Ceapro, IR2Dx to work on pre-diabetes screening test
This article was originally published in Clinica
Canadian biotech firm Ceapro is set to develop its CeaProve point-of-care, pre-diabetes screening test alongside IR2Dx, a company specialising in metabolic diagnostics. The two firms have signed a research and commercial development agreement, which will see a clinical research project established in Germany and Canada to demonstrate CeaProve’s superiority over existing glucose tolerance technology.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals